

SEP licenses distribution rights for Cystistat in Germany and France

Speciality European Pharma Limited (SEP) is pleased to announce that on 1 July 2015 its German and French subsidiaries entered into agreements with Mylan Teoranta Ltd, an Irish affiliate of Mylan Inc. for the exclusive distribution rights for Cystistat[®] in their respective territories.

Cystistat[®] is a medical device for the intravesical treatment of conditions including, but not limited to, cystitis, recurrent bacterial cystitis and radiation induced cystitis in humans.

Commenting on the license agreements, Patrick Banks, Chief Executive Officer of SEP, said:

“These license agreements further enhance SEP’s offering to the urologist and urogynaecologist. The deals follow on from the SEP’s acquisition of Contura A/S in April 2013, which resulted in it entering the medical device market. Cystistat[®] is a complimentary offering for SEP and will be sold into the same target market as a number of SEP’s other products, including Bulkamid[®] and Regurin[®] XL.”

About Cystistat[®]

Cystistat[®] is a sterile sodium hyaluronate solution for temporary replacement of the glycosaminoglycan layer in the bladder, helping to protect it against natural irritants, treating interstitial cystitis. Cystistat[®] is an intravesical therapy which has treated several hundred thousand patients worldwide.

About Bulkamid[®]

Bulkamid[®] is a homogenous hydrophilic hydrogel used in the treatment of female stress urinary incontinence. The product was granted CE approval in 2003 and is currently sold in more than 20 countries worldwide. Bulkamid[®] is delivered to the patient under endoscopic control using the Bulkamid[®] Urethral Bulking System.

About Regurin[®] XL

Regurin[®] XL is a pharmaceutical product indicated to help control the symptoms of an overactive bladder. It is a prolonged release formulation of the active ingredient, trospium chloride and is one of the anticholinergics recommended by NICE for the treatment of urinary incontinence in women. The product is licensed from Madaus GmbH, a member of the Rottapharm group of companies.

About SEP

SEP is the parent company of a European group which specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily upon the fields of urology and urogynaecology. Its lead products are:

Bulkamid[®]
Aquamid[®]
Mitem[®]

Regurin[®] XL

SEP was founded in 2006 and built an experienced and accomplished management team. The licensing of Cystistat[®] adds a further marketed product to the company's offering. In 2013, SEP acquired Contura A/S, a Danish company based in Copenhagen. Contura A/S had two marketed products at the time of its acquisition by SEP, Bulkamid[®] and Aquamid[®]. It also had a number of development programmes focused upon additional uses of its hydrogel technology. SEP has established a sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. SEP has offices in the UK, Denmark, Germany, France and Italy.

-ENDS-

For further information please contact:

SEP
Patrick Banks, Chief Executive Officer

Tel: +44 (0)20 7421 7400